Skip directly to content


Statement on U.S. FDA Report Highlighting Gaps in Pediatric Research
August 27, 2019 – Treatment Action Group (TAG) welcomes a report released last week by the U.S. Food and Drug Administration (FDA) that highlights urgent gaps in pediatric research. This report confirms that we are missing critical information necessary to treat children affected by orphan diseases.

Statement: Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule
August 19, 2019 – Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.

TAG Statement on U.S. FDA Approval of Pretomanid
August 14, 2019 – Treatment Action Group welcomes simpler, shorter treatment options for people with some forms of drug-resistant tuberculosis, while urging additional research and equitable access.

Statement: Treatment Action Group Applauds U.S. Preventive Services Task Force “A” Ratings for Pre-Exposure Prophylaxis and HIV Screening
June 20, 2019 – TAG recently released this statement strongly supporting the final “A” ratings issued by the U.S. Preventive Services Task Force regarding PrEP for individuals highly vulnerable to infection and HIV screening for all Americans between the ages of 15 and 65, including pregnant women.

Advocates Must Press the CDC to Enforce its PrEP Patents in Order to End HIV as an Epidemic
March 28, 2019 – TAG statement calling for advocates to stand with PrEP4All in demanding CDC enforce its PrEP patents. 

ANEA Statement on the President’s Fiscal Year 2020 Budget Proposal
March 15, 2019 – The Act Now End AIDS coalition (Act Now End AIDS) expresses deep disappointment with the President’s Fiscal Year 2020 (FY 20) budget proposal for its failure to provide the fiscal resources, policy leadership, and political vision needed to end the HIV epidemic in the United States. TAG is a member of the coalition.

Treatment Action Group Statement on the President’s Fiscal Year 2020 Budget Proposal
March 13, 2019 – Treatment Action Group (TAG) opposes the President's FY 2020 budget proposal, which makes a mockery of the administration's purported strategy to end AIDS in the United States over the next decade.

Statement from Treatment Action Group on FDA Priority Review of TB Alliance’s New Anti-TB Drug Pretomanid
March 11, 2019 – Treatment Action Group (TAG) welcomes the exciting news of a novel tuberculosis (TB) drug entering priority review by the Food and Drug Administration (FDA).  Pretomanid represents only the fourth new TB drug to go through stringent regulatory review in the past half a century, and the first developed by a not-for-profit organization.

Treatment Action Group Statement on New HIV Remission Case from Stem Cell Transplantation Study
March 4, 2019 - TAG welcomes the report of a possible long-term HIV remission case with similarities to that of Timothy Ray Brown, the lone individual so far considered cured of HIV infection.

TAG and Allies Rally for Affordable HIV Prevention Medication
February 20, 2019 – On Monday February 18, TAG, some of our allies, and a number of elected officials attended a rally in New York City calling on the National Institutes of Health to exercise its march-in rights and break Gildead’s patent on Truvada.

Statement on President Trump’s State of the Union Remarks on Ending the U.S. HIV Epidemic by 2030 from the Act Now: End AIDS Coalition
February 6, 2019 – This statement was released last night by ANEA in response to the President’s SOTU announcement.

Treatment Action Group Generates Novel HIV Cure Research Resources with the Support of the Elizabeth Taylor AIDS Foundation and Macy’s Inc./“Thanks for Giving”
December 6, 2018 – Treatment Action Group has released  a new report focusing on the ethically complex and potentially risky aspect of research aiming to develop a cure for HIV infection: the use of “analytical treatment interruptions” (ATIs) in clinical studies to investigate how HIV viral load rebounds, and whether experimental interventions can limit viral replication after antiretroviral therapy (ART) is interrupted.

Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treated
December 6, 2018 – Advocates scandalized that Gilead's hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billions in profits.

Treatment Action Group Statement on the Reported Birth of Twins with Edited CCR5 Genes
November 26, 2018 – Treatment Action Group (TAG) decries the claimed use of CRISPR technology to edit genes for the HIV co-receptor CCR5 in human embryos for implantation.

Funding for TB Research: Recent Momentum Must Inspire Bold Commitments
September 24, 2018 – In advance of the first-ever United Nations High-Level Meeting on Tuberculosis (TB), a new brief from Treatment Action Group (TAG) — Funding for TB Research: Recent Momentum Must Inspire Bold Commitments — shows that global funding for TB research and development (R&D) reached a new high of USD $767.8 million in 2017.

The TB CAB and TAG Welcome WHO Recommendation of Injectable-Free Regimens for the Treatment of RR/MDR-TB
August 17, 2018 – The Global Tuberculosis Community Advisory Board (TB CAB) and Treatment Action Group (TAG) welcome the new World Health Organization (WHO) recommendation of injectable-free regimens for the treatment of rifampicin- and multidrug-resistant tuberculosis (RR/MDR-TB).

TAG Applauds New York Governor for Committing to Statewide Hepatitis C Elimination Task Force, Action Puts NY at Forefront of Hepatitis C Elimination Efforts in the US
July 27, 2018 – In major step forward, New York State Governor Andrew Cuomo delivered on his earlier commitment to eliminate hepatitis C virus (HCV) with today’s announcement of his intention to appoint a statewide Hepatitis C Elimination Task Force.

Migrants’ Inclusion Central to Achieving HIV and Hepatitis C Targets by 2030
July 26, 2018 – The European African Treatment Advocates Network (EATAN), in partnership with Treatment Action Group (TAG) and other migrant-focused organizations, hosted the European African HIV & Hepatitis C Virus (HCV) Community Summit 2018.

Activists Call on Countries and Donors to Immediately Scale Up Use of Life-Saving TB LAM Test
July 22, 2018 – At the TB 2018 pre-conference held on Sunday 22 July 2018, before the International AIDS Conference in Amsterdam, activists from around the globe called on their countries, development partners, and donors, to end the unacceptable death rates caused by TB in people living with HIV by immediately scaling up the use of TB LAM testing.

TAG Welcomes Price Reductions For TB Medicines
June 19, 2018 – Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required.

TAG Statement on Final Appropriations for Fiscal Year 2018
March 23, 2018 – TAG lauds Congress on rejecting the President’s anti-science rhetoric.

New York Community Groups Call on City, State, Federal Actors to Increase Funding for Tuberculosis
March 22, 2018 –  Advocates alarmed that budget cuts led to first rise in TB cases in New York City in over 25 years.

TAG Applauds Governor Cuomo's Commitment to Eliminate Hepatitis C and Expansion of Enhanced Rental Assistance for People Living with HIV in New York State.
March 16, 2018 – Read the full statement.

Civil society calls on Novartis to end 'bullying tactics' and respect countries' legal rights to make medicines more affordable
March 1, 2018 – TAG rises in solidarity with 11 civil society organizations around the world in opposing the menacing and obstructive tactics by the pharmaceutical giant, Novartis, which seeks to undermine countries' affordable access to medicines.

NY State Medicaid Director Announces Potential Path for Volume Based Deal to Expand Hepatitis C Treatment at Lower Price
February 16, 2018 –  On Monday, February 12th, New York State Medicaid Director Jason Helgerson made news by announcing a potential path forward in the State’s response to its major hepatitis C epidemic at the joint Senate/Assembly budget hearing on Health and Medicaid.

Treatment Action Group Statement on POTUS FY19 Budget Release
February 13, 2018 – Treatment Action Group released a statement today in which it vehemently opposes cuts in the Trump administration’s fiscal year (FY) 2019 budget proposal. Those cuts severely threaten the accelerated progress of recent years towards ending the domestic and global HIV/AIDS, tuberculosis (TB) and hepatitis C virus (HCV) epidemics.

Discriminatory Conscience and Religious Freedom Division Proposed Rule Threatens Our Most Vulnerable Communities
January 19, 2018 – TAG is alarmed by recent actions taken by the Trump administration to subvert the health and wellbeing of women, transgender individuals, and marginalized communities in America.

TAG Mourns the Loss of Mathilde Krim, PhD
January 16, 2018 – TAG mourns the loss of an inspirational, tireless, catalytic leader of our movement. Dr. Krim understood the gravity of the epidemic, in its earliest and darkest days, and was driven by her own remarkable intelligence, fierce commitment to civil rights and social justice, extraordinary social and political networks, and true grit to galvanize funders, scientists, policy leaders, and activists toward a single cause: ending HIV and AIDS as a threat to humanity.

Hasty Passage of the Tax and Health Care Bill
December 21, 2017 – With the hasty passage of the tax and health care bill passed along party-lines yesterday afternoon, Congress has sent a clear message on how they prioritize communities living with, and vulnerable to HIV, tuberculosis (TB) and hepatitis C virus (HCV) in the upcoming mid-term election year.

TAG Statement on Forbidden Words in Budget Documents
December 20, 2017 – Treatment Action Group (TAG) joins the chorus of rational voices expressing outrage at reports that HHS agencies have received instructions to avoid words unpalatable to the Trump administration in their budget requests.

TAG Statement to Human Rights Council on Human Rights Concerns in the UAE
December 13, 2017 – TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).

Changing World Health Organization Global TB Program Leadership
December 1, 2017 – TAG's Executive Director, Mark Harrington, congratulates Dr. Mario Raviglione on his retirement and thanks him for his efforts and the years of collaboration while he was director of the World Health Organization’s (WHO's) Global TB Program.

TAG Applauds Malaysian Government's Decision to Make Generic form of Life-Saving Hep C Cure
September 20, 2017 – The Government of Malaysia reaffirmed its commitment to affordable access to hepatitis C treatment by issuing a compulsory license on sofosbuvir (Sovaldi).

President’s Budget Blueprint Threatens Research Essential to End the Epidemics of HIV/AIDS, TB, and HCV
March 20, 2017 – TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.

Treatment Action Group Lauds Launch of NYC Sexual Health Clinics as Hubs of Comprehensive HIV Prevention and Care
February 17, 2017 – Amid growing concerns about federal government commitments to the national HIV response, TAG applauds the New York City Department of Health and Mental Hygiene (DOHMH) for its radical expansion of the city’s sexual health clinics as hubs of HIV prevention, care, and treatment.

TAG Expands Its End the Epidemic Campaign to Include Southern States Heavily Impacted by HIV
January 30, 2017 – New initiative is under way to strengthen community leadership and mobilization toward ambitious HIV prevention and treatment goals against the backdrop of anticipated shifts in federal support and resources for critical programs.

TAG Urges Action to Oppose Trump’s HHS Pick
January 24, 2017 – TAG Statement for the Record in Opposition to the Nomination of Tom Price for HHS Secretary.

Fair Pricing Coalition Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
December 7, 2016 – The Fair Pricing Coalition announces the release of “Tackling Drug Costs: A 100-Day Roadmap,” an analysis of existing federal statutes and regulations that should be strengthened to dramatically lower the prices of drugs and biologics in the U.S.

Shortage of Injectable Estrogen a Crisis for Transgender Women
December 5, 2016 – Today, The Fenway Institute of Fenway Health, Callen-Lorde Community Health Center, and Treatment Action Group (TAG) released a policy brief documenting the public health emergency created by a shortage of injectable estrogen, and calling on the U.S. Food and Drug Administration (FDA) to be more proactive in resolving the crisis.

HIV Activists Seek to Accelerate Development of Immune Enhancing Therapies for Immunologic Non-Responders
November 30, 2016 – A coalition of HIV/AIDS activists are calling for renewed attention to HIV-positive people termed immunologic non-responders (INRs), who experience suboptimal immune system reconstitution despite years of viral load suppression by antiretroviral therapy. Studies have shown that INR patients remain at increased risk of illness and death compared to HIV-positive people who have better restoration of immune function on current drug therapies.

Funding for Tuberculosis Research Falls to Lowest Level in Seven Years
October 25, 2016—Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to a report issued today by Treatment Action Group (TAG). In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008.

Fair Drug Prices Now Campaign
September 28, 2016 – Treatment Action Group in conjunction with The Fair Pricing Coalition, and the Human Rights Campaign (HRC) Foundation have joined forces to launch #FairDrugPricesNow, a new campaign to mobilize LGBTQ people and their allies to address the continuing rise of prescription drug prices and drug price increases in the United States.

Advocates Call on Clinton to Commit to Ending the Viral Hepatitis Epidemic
September 19, 2016 – Following Secretary Clinton remarks in Cleveland last month on the high price of hepatitis C cures, a group of 130 national advocates today called on the presidential candidate to prioritize the prevention and treatment viral hepatitis. Welcoming Secretary Clinton's focus on high drug prices, the advocates urged her to go further to address the deadliest infectious disease in the US, and to support specific proposals in her platform:

World Hepatitis Day 2016 – Direct-Acting (Antiviral) Generics Work: Free the cure!
July 28, 2016 – To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at

Hepatitis C: no more treatment rationing; universal access to generic medicines everywhere!
April 16, 2016 – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.  

AIDS Advocates from Across the U.S. Call upon Presidential Candidates to Make Ending the Epidemic a Priority
March 15, 2016 – Secretary Clinton's mischaracterization of the Reagan Administration on Friday, March 11, sparked nationwide upset from HIV/AIDS advocates, service providers, people living with HIV, and loved ones of those lost to the epidemic. But it also has created an opportunity to bring HIV/AIDS to the forefront of the conversation during this campaign season.

TAG Welcomes Delamanid’s Inclusion in the Stop TB Partnership’s Global Drug Facility
February 24, 2016 – Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed.

Treatment Action Group hails Governor Cuomo’s proposed legislation allowing minors to maintain confidentiality when obtaining HIV treatment or preventive therapy
February 11, 2016 – "Governor Cuomo continues to provide globally unprecedented leadership with New York State's plan to end AIDS as an epidemic by the year 2020,” said Treatment Action Group executive director Mark Harrington.

TAG’s Response to the U.S. Action Plan for Combating Multidrug Resistant Tuberculosis
January 7, 2016 – Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB. The Administration and Congress must appropriate funding levels to ensure that the U.S. can effectively address MDR-TB.

Tuberculosis Research Funding Crisis Imperils Elimination Goal
November 30, 2015 — Worldwide funding for tuberculosis (TB) research fell $1.3 billion short of global targets in 2014, according to a report released today by Treatment Action Group (TAG). Total funding of US$674,036,492 in 2014 amounted to barely one-third of the US$2 billion experts estimate the world must spend on TB research and development (R&D) each year to eliminate TB. Alarmingly, funding for TB drug research fell by US$25 million compared with 2013. Overall, funding for TB R&D fell by US$12 million.

ACT UP\New York and TAG to Host Town Hall Meeting to Discuss Drastic Cuts to City’s HIV Testing and STD Screening Programs
August 31, 2015– In response to disturbing trends in New York City’s response to the ongoing HIV and STD epidemics, ACT UP\New York and Treatment Action Group (TAG) will host a town hall meeting at the New York City LGBT Center on 13th Street in Manhattan at 6:30 PM on September 1, 2015. ACT UP and TAG seek to push the de Blasio administration to mitigate the massive citywide reduction of sexual health services in recent years, including the March 2015 closure of the Chelsea STD Clinic.

Don't Forget Treatment on World Hepatitis Day
July 28, 2015 – On World Hepatitis Day 2015, as the World Health Organization (WHO) emphasizes prevention, the International Treatment Preparedness Coalition (ITPC) and Treatment Action Group urge pharmaceutical companies and the governments of middle-income countries to act now to facilitate access to treatment for all people with hepatitis C virus (HCV), to avoid needless deaths from HCV complications and to prevent new infections.

Gilead: Stop Blocking Access to Hepatitis C Treatment
May 5, 2015 — On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.

Governor Releases Blueprint to End AIDS in NYS by 2020
April 29, 2015 – New York, NY– Governor Cuomo formally accepted the long-awaited Blueprint to End AIDS at a public event on Wednesday, marking an important step towards fulfilling his commitment to end AIDS in New York State.

Governor Cuomo’s Plan to End AIDS Will Save Lives and Money
April 21, 2015TAG & Housing Works Report Shows Plan To End AIDS By 2020 Will Translate Into $4.5 Billion In Net Medicaid Savings For NY State.

Governor Cuomo’s Ending the Epidemic Task Force Completes Plan to End AIDS in NY State by 2020
January 13, 2015 – Today the Ending the Epidemic Task Force, convened by the New York State Department of Health (DOH) at the behest of Governor Andrew M. Cuomo, completed its comprehensive, rigorous, and unprecedented Plan to End AIDS in New York State by 2020.

Activists Urge Otsuka to Provide Access to TB Drug
October 30, 2014 Tuberculosis (TB) activists interrupted Otsuka’s symposium at the 45th Conference on World Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB (MDR-TB).

NYS Ending Epidemic Task Force
October 14, 2014 – Treatment Action Group (TAG) welcomes today’s announcement by the New York State Department of Health (DOH) of the Ending the Epidemic Task Force to more fully develop Governor Andrew Cuomo’s Plan to End AIDS as an epidemic in New York State by the year 2020.

Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
July 24, 2014 – Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.”

Treatment Action Group Commends Governor Cuomo for Launching Historic New York State Plan to End AIDS
June 29, 2014 – Treatment Action Group (TAG) applauds Governor Andrew M. Cuomo for his full support of a historic community-developed plan to end the AIDS epidemic in New York State by 2020, as announced this morning by the Governor’s office and reported in today’s edition of the New York Times (“Cuomo Plan Seeks to End New York’s AIDS Epidemic,” Anemona Hartocollis, page A18). With this bold initiative, New York State—long the epicenter of the nation’s HIV epidemic—becomes the first jurisdiction anywhere in the world to publicly declare a goal of ending AIDS as an epidemic with the launch of a comprehensive effort to end AIDS deaths and halt new infections by employing state-of-the-art testing, preventive technologies, treatment, and supportive services.

ACT UP to Tom Frieden: You’re MIA on HIV
June 9, 2014 – Members of ACT UP NY, along with Treatment Action Group (TAG) and Atlanta allies, will meet with the Centers for Disease Control & Prevention (CDC)’s HIV prevention personnel in Atlanta, GA. ACT UP will call upon the CDC to meet its commitment of keeping all Americans healthy and to act now upon the promise of TasP, PrEP, and PEP, address social and structural barriers to lifesaving prevention options, and reduce the transmission of HIV in those groups where the incidence is rising.

New Hepatitis Resolution Is Passed at World Health Assembly; Challenges World Health Organization and Member States to Act
May 22, 2014 —Today, four years after introducing its first viral hepatitis resolution, the World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—passed the Hepatitis Resolution, which commits the WHO and United Nations (UN) member states to urgent action to address the global hepatitis pandemic, including that of hepatitis C virus (HCV).

Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
February 28, 2014 – Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies.

Falling Funding for Tuberculosis Research Threatens to Derail TB Elimination Efforts in the United States
March 24, 2014 – The goal of eliminating tuberculosis (TB) as a public health threat in the United States is under threat, a new policy brief released today by Treatment Action Group (TAG) shows. Analysis conducted by TAG reveals that spending on TB research and development (R&D) among U.S. government agencies declined from 2009 to 2012 in the face of budget instability, sequestration, and the rising costs of biomedical research.

CRAG, TAG Welcome Sanofi U.S. Commitment to Reduce the Price of Tuberculosis Drug Rifapentine
December 12, 2013 – The Community Research Advisors Group (CRAG) and Treatment Action Group (TAG) welcome the Sanofi U.S. decision to lower the price of the tuberculosis (TB) drug rifapentine to $32 per 32-tablet blister pack. The company indicates that the new price will become effective in January 2014 under 340(b) Public Health Service pricing.

Treatment Action Group Remembers Nelson Mandela
December 10, 2013 – Treatment Action Group salutes the achievements, life, legacy, and memory of Nelson R. Mandela, who died on December 5.

TAG Applauds $12 Billion Replenishment of Global Fund to Fight AIDS, Tuberculosis and Malaria, and Calls for Greater Flexibility to Support Middle-Income Countries Coping with Large HIV or TB Epidemics
December 3, 2013 – Treatment Action Group applauds the donors who have helped make it possible to save more lives by raising a record-breaking $12 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years. TAG also commends the Obama administration for its generous match of one dollar for every two dollars contributed by other donors, which helped to drive up funding commitments in the current replenishment round.

amfAR and Treatment Action Group Call for a Strategic Research Agenda Needed to End HIV/AIDS in the United States
December 1, 2013 – Today, on World AIDS Day, amfAR, The Foundation for AIDS Research, and Treatment Action Group (TAG) called for a deliberate and expedited research agenda designed to begin to end the AIDS epidemic in the United States. Both organizations noted that in order to achieve this goal, Congress must end sequestration and work to ensure the full implementation of the Affordable Care Act (ACA).

Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing
November 22, 2013 – Treatment Action Group (TAG) congratulates the Committee for Medicinal Products for Human Use (CHMP) for its recommendation to the European Medicines Agency (EMA) to grant marketing approval to delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) now in phase III clinical trials. MDR-TB treatment options that do not include new drugs are long, toxic, difficult to tolerate, and often ineffective.

A Double Blow: Private-Sector Funding for TB Research Drops Sharply Amid Severe Public-Sector Budget Cuts
October 29, 2013  – The 2013 Report on Tuberculosis Research Funding Trends, 2005–2012 finds that funding for tuberculosis research and development (TB R&D) dropped by US$30.4 million compared with 2011—the first time funding has fallen since TAG began tracking investments in 2005. Funding declined for diagnostic, drug, vaccine, and operational research, increasing the likelihood that new tools to fight TB will remain out of reach for the 8.7 million people who develop TB each year.

Treatment Action Group Criticizes European Refusal of New Drug to Fight Tuberculosis
July 29, 2013  Treatment Action Group (TAG) is disappointed by the failure of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB). The drug, one of the first new compounds to fight tuberculosis (TB) in over 40 years, has demonstrated safety and clinical benefit against multidrug-resistant TB (MDR-TB) in clinical trials to date.

2013 Pipeline Report Calls on Leaders to Get the Best HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, and Vaccines to the Most People as Quickly as Possible
June 30, 2013 – HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

Preexposure Prophylaxis (PrEP) Trial among Thai Injection Drug Users Marred by Lack of Response to Community Concerns
June 26, 2013 – On June 12, results from an efficacy trial of tenofovir as pre-exposure prophylaxis (PrEP) against HIV infection in individuals with a self-reported history of injection drug use were published in the Lancet. The trial was sponsored by the U.S. Centers for Disease Control and Prevention (CDC) and took place in Bangkok, Thailand (named the Bangkok Tenofovir Study). The publication was accompanied by a flurry of press releases and drew considerable news coverage due to the documentation of a statistically significant reduction in risk of HIV acquisition of 48.9%.

Children with Drug-Resistant Tuberculosis Require Urgent Attention
March 21, 2013 – Treatment Action Group (TAG), in partnership with the Sentinel Project on Pediatric Drug-Resistant Tuberculosis (Sentinel Project) released today We Can Heal: Prevention, Diagnosis, Treatment, Care and Support: Addressing Drug-Resistant Tuberculosis in Children. This collection, released in anticipation of World TB Day on March 24, calls for urgent attention to the global problem of pediatric drug-resistant tuberculosis (DR-TB).

Treatment Action Group Lauds FDA Approval of First New Tuberculosis Drug in Half a Century
December 31, 2012 – Treatment Action Group (TAG) applauds the accelerated approval today of bedaquiline, the first new approved drug to treat tuberculosis (TB) in over forty years, by the U.S. Food and Drug Administration (FDA). The drug has the potential to improve the treatment for multi-drug resistant (MDR) TB, a particularly deadly and hard to treat form of TB that affects over a million people worldwide, and from which only about half of patients who are treated recover.

Treatment Action Group and European AIDS Treatment Group Applaud UNITAID Agreement to Reduce the Cost of GeneXpert Rapid TB Test
August 7, 2012 – Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG) welcome the announcement that a deal has been reached among PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB).

HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery
July 21, 2012 – On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.

Children with Drug-Resistant TB Make Up the Most Neglected Patient Population
March 22, 2012 – In recognition of World Tuberculosis day on March 24th, Treatment Action Group (TAG) calls for the re-focusing of attention on the tremendous burden that tuberculosis (TB) plays around the world. TB is a disease of the poor – more than 80% of TB cases worldwide arise in the global south. According to the World Health Organization, nearly 4,000 people die every day because of TB.

Obama’s Global, Domestic & HIV Research FY 2013 Budget Backslides on Existing Commitments
February 16, 2012 – Treatment Action Group (TAG) is deeply disappointed by President Obama’s proposed cuts to PEPFAR (President’s Emergency Plan for AIDS Relief) and bilateral TB funds, freezing of NIH (National Institutes of Health) research as well as the insufficient attention to the worsening domestic AIDS crisis in the administration's fiscal year 2013 budget plan.

HCAB Position Statement: Hepatitis C Drug Development and Drug-Drug Interaction Studies
February 2012 - The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV).

We Need the Patent Pool to Work
November 16, 2011 – The exorbitant price of AIDS medicines, especially antiretrovirals, has been one of the main barriers to people with HIV accessing them, especially in developing countries. As activist organisations we have been at the forefront of many of the struggles to make medicines affordable.

Treatment Action Group Issues Latest Update on Global TB R&D Investment Trends
October 26, 2011 – New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels—the first time TAG documents no growth since it began tracking TB research investments in 2005.

Cepheid Pricing of the GeneXpert Machines and Cartridges for Public Sector Use in High TB Burden Areas
September 3, 2011 – On November 12, 2010, the Treatment Action Campaign (TAC) and partners jointly sent an open letter to Cepheid calling for affordable and expanded access to the GeneXpert® MTB/RIF TB diagnostic test. Following this correspondence, TAC and partners had a teleconference with FIND and Cepheid, during which Cepheid indicated that prices for the GeneXpert would be reduced. During December, FIND announced that it had negotiated a volume-based price reduction agreement with Cepheid, lowering the cost of the GeneXpert.

Funding for HIV treatment research exceeded US$2.4 billion in 2009
July 19, 2011 – Data collected for the first time on global investments in HIV treatment-related research and development showed that at least US$ 2.46 billion was available in 2009. The Treatment Action Group, AVAC, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) issued the report which was released at the International AIDS Society's 6th Conference on HIV Pathogenesis, Prevention, and Treatment in Rome, Italy.

2011 Pipeline Report Shows That Medical Prospects for People with HIV, Hepatitis C, and Tuberculosis Have Never Been Better
July 15, 2011 – The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.

Poor Progress Means Multidrug-Resistant Tuberculosis Continues to Spread and Cost Lives
July 7, 2011 – The global response to help countries scale up treatment of multidrug-resistant tuberculosis (MDR-TB) is underfunded and ineffective, according to a new report released today by three medical and medical advocacy organisations. A 20-month effort to reform the Green Light Committee Initiative, a World Health Organization (WHO)-hosted programme designed to help countries gain technical support for scale up of MDR-TB and access to quality-assured MDR-TB drugs, needs to be closely monitored to see if the reforms will address many key bottlenecks.

Bolder Action Needed by Donor Nations, Less Rhetoric in Fight against HIV/AIDS
June 6, 2011 – TAG Statement on the U.N. High Level Meetings on HIV/AIDS Outcome Document.

Treatment Action Group Applauds World Health Organization Endorsement of Rapid TB Test That Could Revolutionize Treatment of Tuberculosis
December 8, 2010  – A new rapid test for tuberculosis (TB) which was just recommended by the World Health Organization (WHO) for widespread use has the potential to revolutionize the world’s fight against the disease, said the Treatment Action Group today,

Letter to Dr. Fauci to Support HIV and Aging Research
September 20, 2010 – The many complications and comorbidities faced by the aging population of HIV positive people in the United States constitute a rapidly growing medical crisis that has been woefully neglected by U.S. research efforts.

TAG Mourns Loss of Dennis deLeon
December 14, 2009 – Statement issued upon the death of Dennis deLeon, long-time Executive Director of the Latino AIDS Commission and former New York City Commissioner of Human Rights.

Treatment Action Group Calls on Obama Administration to Revitalize the World's Fight Against HIV and AIDS
April 27, 2009 – Treatment Action Group (TAG), the nation’s only organization focused exclusively on fighting for better treatments, a cure, and a vaccine for AIDS, today welcomed the Obama administration’s nomination of Dr. Eric Goosby as the next Global AIDS Coordinator in the State Department, which administers the President’s Emergency Plan for AIDS Relief (PEPFAR), the world’s largest international HIV/AIDS prevention and treatment program.

PAVE Gives Pause
May 8, 2008 – TAG Position Statement on PAVE100A Vaccine Trial.

STEP Vaccine Trial Halted
September 24, 2007 – Treatment Action Group (TAG) today issued this statement about the discontinuation of the STEP study, an HIV vaccine efficacy trial conducted by Merck Research Laboratories and the HIV Vaccine Trials Network (HVTN).

TAG Statement on the Life & Legacy of Dr. LEE Jong-Wook, Director, World Health Organization (WHO)
May 8, 2006 – Mark Harrington, Executive Director of Treatment Action Group, a US based research and treatment activist organization, issued this statement.

Statement on the Termination of the SMART Study
January 18, 2006 – The Treatment Action Group (TAG) today expressed disappointment that SMART, a large, international study comparing CD4-guided, intermittent antiretroviral therapy to continuous treatment,  has had to be stopped due to a significantly higher incidence of clinical events in the intermittent treatment arm.

Statement on the Vaccines for the New Millennium Act of 2000
April 19, 2000 – A Statement by Gregg Gonsalves, Policy Director of the Treatment Action Group, on the Vaccines for the New Millennium Act of 2000